Cavitary lung disease in a heart transplant patient

Prasad M. Panse, Eric A. Jensen, Kristopher W. Cummings, Clinton E. Jokerst, Henry D. Tazelaar, Michael Gotway

Research output: Contribution to journalArticle

Abstract

Invasive fungal infections are highly aggressive and occur almost exclusively in severely immunocompromised patients, such as solid organ and hematopoietic stem cell transplant recipients, patients with profound and prolonged neutropenia, patients with diabetes mellitus (particularly with ketoacidosis), and those with other conditions. The most common invasive fungal infection in these patients is invasive aspergillosis. However, use of antifungal prophylaxis, among other considerations, leads to a relative increase in non-Aspergillus invasive fungal infections, such as mucormycosis. Mucormycosis may present in a manner that clinically and radiographically resembles invasive aspergillosis, but distinguishing these 2 infections is important because the common treatment for invasive aspergillosis - voriconazole - is not active against mucormycosis. Although the diagnosis of mucormycosis often requires microbiological identification of the organism, several computed tomographic features, including the reverse halo sign, multiple (> 10) nodules, micronodules, and pleural effusion, may favor the diagnosis of mucormycosis over invasive aspergillosis. Such a distinction may prove very useful when a confirmatory tissue diagnosis is not possible. The mainstay of treatment for mucormycosis includes reversal of identifiable risk factors, surgical debridement of necrotic tissue, and appropriate antifungal therapy. In selected patients, iron chelation therapy may be of benefit.

Original languageEnglish (US)
Pages (from-to)188-192
Number of pages5
JournalClinical Pulmonary Medicine
Volume23
Issue number4
DOIs
StatePublished - 2016

Fingerprint

Mucormycosis
Lung Diseases
Aspergillosis
Transplants
Chelation Therapy
Ketosis
Immunocompromised Host
Debridement
Pleural Effusion
Hematopoietic Stem Cells
Neutropenia
Diabetes Mellitus
Therapeutics
Iron
Infection
Invasive Fungal Infections

Keywords

  • Angioinvasive
  • Cavity
  • Fungal infection
  • Heart transplant
  • Mucormycosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Panse, P. M., Jensen, E. A., Cummings, K. W., Jokerst, C. E., Tazelaar, H. D., & Gotway, M. (2016). Cavitary lung disease in a heart transplant patient. Clinical Pulmonary Medicine, 23(4), 188-192. https://doi.org/10.1097/CPM.0000000000000164

Cavitary lung disease in a heart transplant patient. / Panse, Prasad M.; Jensen, Eric A.; Cummings, Kristopher W.; Jokerst, Clinton E.; Tazelaar, Henry D.; Gotway, Michael.

In: Clinical Pulmonary Medicine, Vol. 23, No. 4, 2016, p. 188-192.

Research output: Contribution to journalArticle

Panse, PM, Jensen, EA, Cummings, KW, Jokerst, CE, Tazelaar, HD & Gotway, M 2016, 'Cavitary lung disease in a heart transplant patient', Clinical Pulmonary Medicine, vol. 23, no. 4, pp. 188-192. https://doi.org/10.1097/CPM.0000000000000164
Panse, Prasad M. ; Jensen, Eric A. ; Cummings, Kristopher W. ; Jokerst, Clinton E. ; Tazelaar, Henry D. ; Gotway, Michael. / Cavitary lung disease in a heart transplant patient. In: Clinical Pulmonary Medicine. 2016 ; Vol. 23, No. 4. pp. 188-192.
@article{a06be8a949a1400e8c7e2d7b71d87254,
title = "Cavitary lung disease in a heart transplant patient",
abstract = "Invasive fungal infections are highly aggressive and occur almost exclusively in severely immunocompromised patients, such as solid organ and hematopoietic stem cell transplant recipients, patients with profound and prolonged neutropenia, patients with diabetes mellitus (particularly with ketoacidosis), and those with other conditions. The most common invasive fungal infection in these patients is invasive aspergillosis. However, use of antifungal prophylaxis, among other considerations, leads to a relative increase in non-Aspergillus invasive fungal infections, such as mucormycosis. Mucormycosis may present in a manner that clinically and radiographically resembles invasive aspergillosis, but distinguishing these 2 infections is important because the common treatment for invasive aspergillosis - voriconazole - is not active against mucormycosis. Although the diagnosis of mucormycosis often requires microbiological identification of the organism, several computed tomographic features, including the reverse halo sign, multiple (> 10) nodules, micronodules, and pleural effusion, may favor the diagnosis of mucormycosis over invasive aspergillosis. Such a distinction may prove very useful when a confirmatory tissue diagnosis is not possible. The mainstay of treatment for mucormycosis includes reversal of identifiable risk factors, surgical debridement of necrotic tissue, and appropriate antifungal therapy. In selected patients, iron chelation therapy may be of benefit.",
keywords = "Angioinvasive, Cavity, Fungal infection, Heart transplant, Mucormycosis",
author = "Panse, {Prasad M.} and Jensen, {Eric A.} and Cummings, {Kristopher W.} and Jokerst, {Clinton E.} and Tazelaar, {Henry D.} and Michael Gotway",
year = "2016",
doi = "10.1097/CPM.0000000000000164",
language = "English (US)",
volume = "23",
pages = "188--192",
journal = "Clinical Pulmonary Medicine",
issn = "1068-0640",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cavitary lung disease in a heart transplant patient

AU - Panse, Prasad M.

AU - Jensen, Eric A.

AU - Cummings, Kristopher W.

AU - Jokerst, Clinton E.

AU - Tazelaar, Henry D.

AU - Gotway, Michael

PY - 2016

Y1 - 2016

N2 - Invasive fungal infections are highly aggressive and occur almost exclusively in severely immunocompromised patients, such as solid organ and hematopoietic stem cell transplant recipients, patients with profound and prolonged neutropenia, patients with diabetes mellitus (particularly with ketoacidosis), and those with other conditions. The most common invasive fungal infection in these patients is invasive aspergillosis. However, use of antifungal prophylaxis, among other considerations, leads to a relative increase in non-Aspergillus invasive fungal infections, such as mucormycosis. Mucormycosis may present in a manner that clinically and radiographically resembles invasive aspergillosis, but distinguishing these 2 infections is important because the common treatment for invasive aspergillosis - voriconazole - is not active against mucormycosis. Although the diagnosis of mucormycosis often requires microbiological identification of the organism, several computed tomographic features, including the reverse halo sign, multiple (> 10) nodules, micronodules, and pleural effusion, may favor the diagnosis of mucormycosis over invasive aspergillosis. Such a distinction may prove very useful when a confirmatory tissue diagnosis is not possible. The mainstay of treatment for mucormycosis includes reversal of identifiable risk factors, surgical debridement of necrotic tissue, and appropriate antifungal therapy. In selected patients, iron chelation therapy may be of benefit.

AB - Invasive fungal infections are highly aggressive and occur almost exclusively in severely immunocompromised patients, such as solid organ and hematopoietic stem cell transplant recipients, patients with profound and prolonged neutropenia, patients with diabetes mellitus (particularly with ketoacidosis), and those with other conditions. The most common invasive fungal infection in these patients is invasive aspergillosis. However, use of antifungal prophylaxis, among other considerations, leads to a relative increase in non-Aspergillus invasive fungal infections, such as mucormycosis. Mucormycosis may present in a manner that clinically and radiographically resembles invasive aspergillosis, but distinguishing these 2 infections is important because the common treatment for invasive aspergillosis - voriconazole - is not active against mucormycosis. Although the diagnosis of mucormycosis often requires microbiological identification of the organism, several computed tomographic features, including the reverse halo sign, multiple (> 10) nodules, micronodules, and pleural effusion, may favor the diagnosis of mucormycosis over invasive aspergillosis. Such a distinction may prove very useful when a confirmatory tissue diagnosis is not possible. The mainstay of treatment for mucormycosis includes reversal of identifiable risk factors, surgical debridement of necrotic tissue, and appropriate antifungal therapy. In selected patients, iron chelation therapy may be of benefit.

KW - Angioinvasive

KW - Cavity

KW - Fungal infection

KW - Heart transplant

KW - Mucormycosis

UR - http://www.scopus.com/inward/record.url?scp=84978274877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978274877&partnerID=8YFLogxK

U2 - 10.1097/CPM.0000000000000164

DO - 10.1097/CPM.0000000000000164

M3 - Article

AN - SCOPUS:84978274877

VL - 23

SP - 188

EP - 192

JO - Clinical Pulmonary Medicine

JF - Clinical Pulmonary Medicine

SN - 1068-0640

IS - 4

ER -